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Recombinant envelope glycoproteins prepared from a subtype B (MN) strain and a subtype E (CM244) strain of HIV-1 were
combined to create a bivalent vaccine (B/E) effective against viruses circulating in the United States and Asia. Combining the
two antigens resulted in formulations that increased the breadth and potency of the inter-subtype neutralizing response.
Antibodies to the bivalent vaccine formulation neutralized viruses possessing diverse phenotypes, including syncytia-
inducing and non-syncytia-inducing primary isolates, viruses using either the CCR5 or the CXCR4 chemokine receptors, and
viruses differing in their sensitivity to soluble CD4. These studies demonstrate for the first time that the magnitude and quality
of the immune response to HIV-1 can be improved by combining recombinant envelope glycoproteins from different genetic
subtypes. © 1999 Academic PressKey Words: HIV; vaccine; CCR5; CXCR4; antibodies; neutralization.
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bIntroduction. Molecular epidemiologic studies have
efined approximately nine genetically distinct subtypes
f HIV-1 (33). In some geographic regions (e.g., sub-
aharan Africa) multiple subtypes (e.g., A, C, D, G, and O)
f HIV-1 are in circulation (32, 36), whereas in other
eographic regions (e.g., United States, western Europe,
hailand) the representation of genetic subtypes is more
estricted, with the majority of infections limited to a
ingle subtype (e.g., B or E) (19, 22, 33, 40). Because
mino acid sequence variation in the envelope glyco-
roteins varies from 25 to 30% between subtypes, it has
een speculated that multivalent vaccines, containing
iral antigens from several genetically distinct viruses,
ill be required for vaccines to provide protective immu-
ity against all of the genetic subtypes circulating in
uman populations.
However, the relevance of genetic subtypes to virus
eutralization serotypes is unclear (31). It has long been
nown that antisera from individuals infected with tem-
orally and geographically distinct isolates of HIV-1 ex-
ibit a high level of inter-subtype cross-reactivity, as well
s significant inter-subtype virus neutralizing activity (20,
1 To whom correspondence and reprint requests should be ad-
ressed at current address: VaxGen, Inc., 1000 Marina Boulevard, 2nd
loor, Brisbane, CA 94005. Fax: (650) 624-1001. E-mail: pwb@
axgen.com.
2 Current address: Virologic, Inc., South San Francisco, CA 94080.
H3 Current address: VaxGen, Inc., South San Francisco, CA 94080.
12). Limited data are available concerning the ability of
ecombinant HIV-1 envelope glycoproteins to stimulate
ntibody responses capable of inter-subtype neutraliza-
ion. It is not known whether the breadth of inter-subtype
ross-reactivity seen in some HIV-11 human sera can be
uplicated by immunization with recombinant subunit
accines or whether this activity occurs as a unique
onsequence of long-term exposure to the swarm of
elated virus quasi-species that arise during the course
f chronic HIV-1 infection (9, 28). Moreover, much of the
ata that is available regarding inter-subtype neutraliza-
ion was obtained using T-cell-tropic viruses. It is now
ecognized that HIV-1 exhibits two distinct phenotypes
elated to virus tropism: T-cell-tropic viruses and mac-
ophage-tropic viruses. T-cell-tropic viruses are readily
eutralized in vitro, can be cultured in T-cell lines, induce
yncytia formation, and require the CXCR4 chemokine
eceptor for infection. Macrophage-tropic viruses are dif-
icult to neutralize in vitro, are resistant to growth in T-cell
ines, are unable to induce syncytia formation, and re-
uire the CCR5 chemokine receptor for infection. Based
n these differences, it has been speculated that the
readth of virus neutralizing activity elicited by candidate
accines might be improved by including antigens de-
ived from both macrophage-tropic and T-cell-tropic
trains of HIV-1.
In the present study rabbits were immunized with
ivalent vaccine formulations containing recombinant
IV-1 envelope glycoproteins from a subtype B, T-cell-
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2 RAPID COMMUNICATIONropic virus (MN-rgp120) and a subtype E, macrophage-
ropic virus (A244-rgp120). Experience with other recom-
inant envelope glycoproteins (IIIB-rgp120, MN-rgp120)
as shown that antibody responses to gp120 in rabbits
7) resemble antibody responses to rgp120 in humans (3,
9). We found that antisera from rabbits immunized with
gp120 were effective in neutralizing macrophage-tropic
nd T-cell-tropic viruses from subtype B and subtype E
trains of HIV-1. In principle, a vaccine prepared from the
ntigens described in this report might be useful in
acific Rim countries where both subtype B and subtype
viruses are in circulation.
Results. gp120-Binding Studies. Animals were immu-
ized with MN-rgp120 alone, with A244-rgp120 alone,
nd with various mixtures of these two antigens (Fig. 1).
igh levels of antibodies (range 5.04 to 5.60 log10 titers)
eactive with both MN-rgp120 and A244-rgp120 gp120
ere observed after the third booster immunization in
he animals immunized with all formulations tested (Fig.
). Formulation-dependent differences in titers to either
ntigen were not observed. These data suggested that
ll of the bivalent formulations were comparably immu-
ogenic and that the major antigenic determinants were
onserved between the two different viral proteins.
CM244 is a CCR5-Dependent Macrophage-Tropic Vi-
us. Previous studies have shown that HIV-1MN pos-
essed a syncytia-inducing, CD4-sensitive, CXCR4-de-
endent phenotype (11, 12). Because the phenotype of
FIG. 1. Antibody binding to MN-rgp120 and A244-rgp120. Two rabbits
ere immunized with various mixtures of MN-rgp120 and A244-rgp120.
atios indicate the composition of different vaccine formulations. For
xample, a 4/1 ratio indicates a formulation consisting of four parts
N-rgp120 and one part A244-rgp120. Sera were collected 2 weeks
fter the fourth immunization and assayed by ELISA for antibody bind-
ng to MN-rgp120 and A244-rgp120. Data represent the mean log
nd-point dilution titers for pairs of rabbits immunized with each for-
ulation. Black bars indicate antibody binding to MN-rgp120; cross-
atched bars indicate antibody binding to A244rgp120.M244 virus had not previously been defined, chemo- tine coreceptor usage and soluble CD4 sensitivity stud-
es were carried out. It was observed that the CM244
solate was resistant to stromal-derived factor (SDF), a
igand for CXCR4 (37), but was sensitive to neutralization
y Rantes (1, 13), a ligand for CCR5 (Fig. 2A). These
esults suggested that the CM244 isolate utilized the
CR5 chemokine receptor typically used by macro-
hage-tropic viruses (1, 10, 12) and not the CXCR4 che-
okine receptor used by T-cell-tropic viruses (15). In
ther studies, the sensitivity of the CM244 isolate to
nhibition by CD4-IgG was measured (Fig. 2B). Like other
rimary isolates of HIV-1 (2, 11), the CM244 isolate was
FIG. 2. Chemokine and CD4-IgG sensitivity of the CM244 isolate of
IV-1. (A) Various concentrations of the Rantes and SDF chemokines
ere added to cultures of PBMCs prior to the addition of CM244 virus.
he effect of the CXCR4 ligand SDF on the growth of the CM244 virus
open circles) was compared to the effect of the CCR5 ligand, Rantes
filled circles). (B) The sensitivity of the MN and CM244 isolates of HIV-1
o inhibition by soluble CD4-IgG was compared. Diluted stocks of the
M244 isolate (filled circles) or the MN isolate (open circles) were
reated with various concentrations of CD4-IgG before being added to
ultures of PHA-activated PBMCs. Virus replication was monitored by
easurement of p24 production using a commercial ELISA. The pro-
uction of p24 antigen in the presence of chemokines was normalized
o p24 production in control cultures, without added inhibitors.
a
I
C
o
g
v
s
t
A
t
h
(
H
i
1
p
a
r
M
h
1
3
s
f
c
E
s
1
1
o
t
o
b
s
n
o
v
i
t
s
n
w
s
c
s
M
s
H
c
A
t
t
S
e
l
p
c
T
c
o
s
a
b
s
(
t
w
i
W
f
1
b
i
l
M
s
s
t
i
t
l
t
o
P
v
w
r
3RAPID COMMUNICATIONt least 100-fold more resistant to neutralization by CD4-
gG (0.2 mg/ml) than was the MN strain (0.002 mg/ml
D4-IgG) of HIV-1 (Fig. 2B). These results, together with
ther studies demonstrating that CM244 was unable to
row in cell lines commonly used to propagate CXCR4
iruses, such as H9 and MT4 (data not shown), demon-
trate that the CM244 virus possessed a phenotype
ypical of CCR5-dependent, macrophage-tropic viruses.
Neutralization of Viruses Used to Produce Vaccine
ntigens. Initial experiments examined the ability of an-
isera to MN-rgp120 and A244-rgp120 to neutralize the
omologous MN and CM244 viruses. Previous studies
25, 26, 30) have shown that T-cell-tropic viruses (e.g.,
IV-1MN) are extraordinarily sensitive to in vitro neutral-
zation and often exhibit neutralization titers in the range
023 to 1025. In contrast, macrophage-tropic viruses have
roved to be resistant to neutralization by polyclonal
ntisera and, at best, give neutralization titers in the
ange 1021 to 1022.5 (9, 25, 31). We found that antisera to
N-rgp120 neutralized HIV-1MN at high dilution and ex-
ibited low levels of neutralizing activity (mean titer of
:75) against the subtype E, CM244 virus (Table 1, Fig.
A). Neutralization of CM244 was somewhat unexpected
ince the amino acid sequence of MN-rgp120 differs
rom CM244-rgp120 by approximately 30% (27) and be-
ause others have reported that neutralization of subtype
viruses by antisera to subtype B viruses is subtype
pecific (25).
When antisera to A244-rgp120 were examined (Table
, Fig. 3B), high levels of neutralizing activity (mean titer
TABLE 1
Neutralization of CCR5-Dependent, Macrophage-Tropic HIV-1 Iso-
ates with Rabbit Antisera to Bivalent Subtype B/E Vaccine Formula-
ions
Ratio MN/A244
Viruses
CM244
(E)
302031
(E)
301660
(B)
MN 75 15 105
4:1 900 105 225
2:1 290 45 215
1:1a 1300 150 110
1:2 225 75 188
1:4 450 40 10
A244a 1475 100 ,10
HIV1 Pool (B) 700 ,10 30
HIV1 Pool (E) 900 100 83
Note. Data represent mean neutralization titers obtained from pairs
f rabbits immunized with the vaccine formulations indicated. HIV1
ool (E) represents pooled sera from individuals infected with subtype
iruses. HIV1 Pool (B) represents pooled sera from individuals infected
ith subtype B viruses.
a Data represent mean neutralization titers obtained from two pairs of
abbits immunized with two different lots of vaccine antigen.:1475) against the parental CM244 strain of HIV-1 were tbserved when assayed in PBMC culture. When antisera
o A244-rgp120 were tested for activity against HIV-1MN,
ne of four sera exhibited significant neutralizing anti-
odies (titer of 1:270) while the remaining three sera
howed no neutralizing activity against this virus (data
ot shown). In all cases, neutralizing titers to the homol-
gous virus were greater than titers to the heterologous
irus. Together, these experiments demonstrated that
mmunization with rgp120 from either subtype B or sub-
ype E vaccines can elicit antibodies capable of inter-
ubtype virus neutralization, but that the inter-subtype
eutralizing response elicited by monovalent vaccines
as sporadic and inconsistent.
To determine whether the relative amount of the
ubtype B and subtype E antigens in bivalent vac-
ines affected the potency of the virus neutralizing re-
ponse, antisera raised against five different mixtures of
N-rgp120 and A244-rgp120 were examined. All anti-
era to the bivalent formulations were able to neutralize
IV-1CM244 and HIV-1MN (Table 1, Fig. 3C) with mean titers
omparable to those obtained with monovalent vaccines.
s would be expected, antisera to the bivalent formula-
ions were more effective in neutralizing the CM244 virus
han antisera to the monvalent MN-rgp120 formulation.
imilarly, antisera to the bivalent formulations were more
ffective in neutralizing the MN virus than the monova-
ent sera to A244-rgp120. No indication of antigenic com-
etition or interference was detected when bivalent vac-
ines were compared to monovalent vaccines.
Neutralization of Heterologous Primary Macrophage
ropic Viruses by Bivalent Vaccines. Further studies were
arried out to examine neutralization of primary isolates
f HIV-1 unrelated to the vaccine immunogens. For these
tudies we employed a subtype B isolate termed 301660
nd a subtype E isolate termed 302031. Both viruses had
een cultured exclusively in PBMCs and possessed non-
yncytium-inducing, CCR5, CD4-resistant phenotypes
Table 2). We observed that antisera to MN-rgp120 neu-
ralized the 301660 virus, with a mean titer of 1:105,
hereas antisera to A244-rgp120 failed to exhibit signif-
cant neutralizing activity against this virus (Table 1).
hen sera from rabbits immunized with the five bivalent
ormulations were examined, mean titers ranging from
:10 to 1:225 were observed (Table 1, Fig. 3D). As would
e expected, the sera to formulations that were predom-
nantly A244-rgp120 (A244-rgp120 alone and the formu-
ation containing four parts A244-rgp120 and one part
N-rgp120) exhibited the lowest neutralizing titers.
Antisera to the bivalent vaccine formulations were
imilarly tested for the ability to neutralize other Thai,
ubtype E, primary isolates (Table 1, Fig. 3D). We found
hat all of the antisera tested possessed virus neutraliz-
ng activity against the 302031 isolate (Table 1), though
he peak titers to this virus were lower than the peak
iters to the CM244 and 301660 strains of HIV-1. As would
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4 RAPID COMMUNICATIONe expected, the lowest virus neutralization titers were
bserved in rabbits that received MN-rgp120 alone,
hereas all of the sera to the bivalent formulations were
ble to neutralize this virus, with mean titers ranging
rom 1:40 to 1:150 (Table 1).
Subtype-specific neutralizing activity was rare in these
tudies and was seen only with antisera raised against
ormulations containing a high percentage of A244-
gp120 and a low percentage of MN-rgp120. Thus, anti-
era from animals immunized with the monovalent A244-
FIG. 3. Neutralization of subtype B and subtype E viruses by an
eutralization of the MN strain of HIV-1 by rabbit antisera to MN-rgp1
f the CM244 strain of HIV-1 by antisera to MN-rgp120 (open circles) or
ircles) and the CM244 strain of HIV-1 (filled circles) by antisera fro
eutralization of the subtype B, CCR5-dependent, 301660 strain of HIV
open circles) by the same antisera shown in C. Virus replication was m
roduction of p24 antigen in the presence of antibodies was normalized
ontrol sera.gp120 vaccine exhibited little or no neutralizing activity lgainst the 301660 virus. Similarly, the antisera raised
gainst the bivalent formulation consisting of one part
N-rgp120 and four parts A244-rgp120 also exhibited
ow virus neutralizing titers. These results (Table 1) sug-
ested that the potency of bivalent B/E vaccines was
elatively insensitive to the relative amount of each anti-
en, provided that the preparations contained at least
3% MN-rgp120.
To gain perspective on the magnitude of the virus
eutralizing response elicited by the recombinant enve-
to monovalent and bivalent subtype B/E vaccine formulations. (A)
n circles) or antisera to A244-rgp120 (filled circles). (B) Neutralization
gp120 (filled circles). (C) Neutralization of the MN strain of HIV-1 (open
bbit immunized with a mixture of MN-rgp120 and A244-rgp120. (D)
d circles) and the subtype E, CCR5-dependent 302031 strain of HIV-1
ed by measurement of p24 production using a commercial ELISA. The
production in control cultures in the presence of preimmune or normaltisera
20 (ope
A244-r
m a ra
-1 (fille
onitor
to p24ope glycoproteins, neutralization experiments were car-
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5RAPID COMMUNICATIONied out with sera from HIV-1-infected humans. We found
hat the antibody response elicited in humans infected
ith subtype E viruses was more effective against the
ubtype E viruses (CM244 and 302031) than against the
ubtype B viruses (Table 1). For example, the titer to
IV-1MN was only 1:67 (data not shown), whereas the titer
o 301660 was 1:83. Surprisingly, pooled sera from indi-
iduals infected with subtype B viruses showed strong
ctivity (1:700) against the CM244 virus, but weak activity
gainst the 301660 virus. This result may reflect the fact
hat 301660 is known to be a difficult virus to neutralize
14) and that the monoclonal antibody (2G12) best able to
eutralize this virus recognizes an epitope that is con-
erved between different genetic subtypes (e.g., subtype
viruses) (41). The present result suggests that subtype
viruses may be able to elicit antibodies to a similar
eutralizing epitope that is conserved across genetic
ubtypes.
Neutralization of Diverse Primary Isolates with Anti-
era to Bivalent B/E Vaccine. Additional virus neutraliza-
ion studies were carried out using antiserum from a B/E
accine immunized rabbit that gave good neutralizing
esponse against the viruses in Table 2. In these studies,
irus neutralization activity was measured for five addi-
ional primary isolates. The viruses used in this experi-
ent possessed a number of interesting genotypic
nd phenotypic properties (Table 2). Neutralization of
IV-1JRcsf demonstrated that the B/E vaccine could neu-
ralize a prototypic CD4-resistant, CCR5-dependent,
acrophage-tropic virus. Neutralization of the Brazilian
solate BZ167 demonstrated that the bivalent formulation
ould elicit antibodies able to neutralize a syncytium-
nducing, T-cell-tropic, subtype B, primary isolate that
iffered from MN in the V3 domain subtype B consensus
ND sequence (i.e., IRIGPGRTF rather than IHIGPGRAF)
T
Neutralization of Primary and Macrophage-Tropi
Virus Subtype Origin SI/NSI
01660 B USA NSI
Rcsf B USA NSI
Z167 B Brazil SI
H92014 B9 Thailand NSI
H92009 E Thailand NSI
M244 E Thailand NSI
02051 E Thailand SI
02031 E Thailand NSI
a SI/NSI indicates syncytia-inducing or non-syncytia-inducing phenoty
he CXCR4 (R4) ligand, or Rantes, the CCR5 (R5) ligand. B/E Neut. titer in
ble to inhibit virus growth by 50%. HIV1 Neut. titer indicates the dilut
b GenBank accession numbers and or references for the sequences22). Similar results were obtained with the Thai B9 iso- date, TH92014, and the T-cell-tropic Thai E isolate, 302051,
oth of which differed from MN-rgp120 and A244-rgp120
t the V3 domain crown sequence (Table 2) yet were
eutralized, albeit at low titers, by the bivalent B/E anti-
era. Finally, neutralization of the Thai TH92009, CM244,
nd 302031 viruses demonstrated that bivalent B/E sub-
nit vaccines can neutralize a variety of CCR5-depen-
ent, subtype E, primary isolates that contain the con-
ensus Thai E V3 domain crown sequence GPGQVF
equence (Table 2). For the purpose of comparison we
ested all of the viruses in this panel for sensitivity to
eutralization by pooled sera from randomly selected
IV-1-infected individuals collected in the United States
HIV1 neutralization titers). We found that the magnitude
f the inter-subtype neutralizing activity of the B/E rabbit
erum was similar to that of our pooled HIV1 sera and
hat the titers measured in our assay were similar to
hose reported for sera from long-term survivors (9) and
ther sera from HIV-1-infected individuals (25, 26, 30).
Discussion. These studies resulted in three important
bservations: (i) mixing antigens from different HIV-1
ubtypes can expand the breadth of virus neutralizing
ctivity compared with monovalent vaccines, (ii) the qual-
ty and magnitude of the antibody response elicited by
ivalent gp120-based vaccines are similar to those ob-
erved in sera from HIV-1-infected humans, and (iii) an-
isera to recombinant gp120 can elicit antibodies able to
eutralize both T-cell-tropic (CXCR4-dependent) and
acrophage-tropic (CCR5-dependent) viruses.
We found that both MN-rgp120 and A244-rgp120 are
mmunogenic in rabbits and elicit high titers of cross-
eactive antibodies. Antibody binding to gp120 sug-
ested that the immunodominant domains of gp120 are
onserved between subtype B and subtype E viruses.
he magnitude of the antibody responses (end-point
tes by Rabbit Antisera to Bivalent B/E Vaccinea
mokine
ceptor
B/E Neut.
titer
HIV1 Neut.
titer
V3
Crownb
5 150 30 GPGRAF
5 30 60 GPGRAF
4 100 100 GPGRTF
5/X4 20 100 GPGRAW
5 20 ,10 GPGQVF
5 1000 700 GPGQVF
4 50 ,10 GPGRVY
5 150 ,10 GPGQVF
mokine receptor usage was defined by sensitivity to inhibition by SDF,
the dilution of rabbit sera to a mixture of A244-rgp120 and MN-rgp120
ooled HIV-11 human sera able to inhibit virus growth by 50%.
are provided under Materials and Methods.ABLE 2
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6 RAPID COMMUNICATIONabbits was similar (1024 to 1025) to that measured in
era from HIV-1-infected humans (M. Peterson, VaxGen,
nc., personal communication). Experiments with the
onovalent MN-rgp120 and the A244-rgp120 vaccines
emonstrated that inter-subtype virus neutralizing anti-
odies could be elicited by either antigen. However, the
nter-subtype neutralizing responses obtained with
onovalent vaccines were often weak and varied from
abbit to rabbit. Studies with bivalent B/E vaccine formu-
ations demonstrated that more potent and consistent,
nter-subtype, virus neutralizing responses could be elic-
ted by vaccine formulations when antigens from genetic
ubtypes were combined. Experiments in which the rel-
tive proportion of subtype B and subtype E antigens
ere varied demonstrated that the MN-rgp120 and A244-
gp120 antigens were similarly immunogenic and sug-
ested that a broad range of formulations are effective in
liciting inter-subtype neutralizing responses.
A significant result of these studies was the observa-
ion that both subtype E and subtype B viruses, exhibiting
henotypic properties associated with macrophage-
ropic viruses (i.e., NSI, CD4-resistant, CCR5-dependent),
ould be neutralized by antisera to MN-rgp120, antisera
o A244-rgp120, or antisera to a bivalent vaccine consist-
ng of a mixture of A244-rgp120 and MN-rgp120. This
bservation demonstrates that recombinant gp120 is
ble to elicit antibodies that neutralize CCR5-dependent
macrophage-tropic) isolates of HIV-1 and is consistent
ith studies showing that most monoclonal antibodies
ble to neutralize macrophage-tropic, primary isolates of
IV-1 bind to MN-rgp120 (16, 18, 30). Several previous
tudies have failed to detect antibodies capable of neu-
ralizing macrophage-tropic viruses with sera of animals
r human volunteers immunized with rgp120 (17, 26, 43).
he difference between the present studies and the
revious studies appears attributable to quantitative dif-
erences in antibody titers, controlling assay variables
e.g., PBMCs from a single donor), and improvements to
he assay (maintaining antisera in the virus culture for 3
ays prior to wash-out).
These studies document that the magnitude and spec-
ficity of the virus neutralizing response to CXCR4-depen-
ent (T-cell-tropic) and CCR5-dependent (macrophage-
ropic) viruses elicited by recombinant antigens de-
cribed in this paper are similar to those seen in sera
rom humans chronically infected with HIV-1 (25, 26, 31).
hus, like HIV-11 serum, neutralization titers in the range
f 1023 to 1025 were obtained with CXCR4-dependent
T-cell-tropic) viruses (e.g., MN), and neutralization titers
n the range of 1021 to 1022.5 were obtained with CCR5-
ependent (macrophage-tropic) viruses.
Recently, some investigators have suggested that a
0% virus neutralization end-point may be more informa-
ive for measuring neutralization of macrophage-tropic
solates than a 50% end-point (used in the present stud-
es). We disagree with this view, particularly with respect ao the analysis of polyclonal antisera. While many ran-
omly selected sera from HIV-1-infected humans neutral-
ze primary macrophage tropic isolates using a 50%
ut-off, few exhibit robust neutralization with a 90% cut-
ff (31). Thus significantly less information can be ex-
ected from a 90% end-point compared to a 50% end-
oint. In addition, even when it is possible to detect
eutralization at a 90% cut-off with polyclonal sera, it is
sually only at low dilution (i.e., ,1:10) where nonspe-
ific inhibition is most prone to occur. Finally, a recent
IH study suggests that only a few of the most highly
elected and potent monoclonal antibodies could con-
istently achieve 90% neutralization of a panel of primary
CR5-dependent viruses and that results varied consid-
rably between laboratories (14). Thus, while the 90%
ut-off may be useful for documenting the neutralizing
ctivity of a few unusually potent polyclonal (9) and
onoclonal antibodies (41), the assay is difficult to re-
roduce and is insensitive to the magnitude and speci-
icity of the immune response induced by natural HIV-1
nfection.
Previous studies suggested that recombinant gp120
nduces antibodies able to neutralize CCR5-dependent
iruses, but that the concentration of these antibodies
aries from serum to serum. Thus, when antibodies were
oncentrated from volunteers immunized with MN-
gp120 in a manner similar to that used in the production
f hyperimmune IgG, we observed neutralization of
CR5-dependent viruses (5). Recent data from a Phase I
uman clinical trial in Thailand (v0633g) with a monova-
ent vaccine suggest that antibodies capable of neutral-
zing CCR5-dependent viruses can be elicited in humans,
ut do not appear until after the 12-month booster injec-
ion when immunized according to a 0-, 1-, 6-, and 12-
onth immunization regime (5, 29). These results sug-
est that an affinity maturation step may be required for
he development of antibodies able to neutralize CCR5-
ependent, NSI strains of HIV-1.
In conclusion, we found that combining antigens rep-
esenting two distinct genetic subtypes could increase
he reproducibility and potency of the inter-subtype, virus
eutralizing antibody response. Antisera raised against
ivalent vaccines exhibited neutralizing activity against
iruses that varied in cellular tropism, chemokine recep-
or usage, CD4 sensitivity, and syncytium-inducing ca-
acity. However, the extent to which in vitro neutralization
ssay results correlate with protection from virus infec-
ion in vivo is unknown. Ultimately the success or failure
f any vaccine depends on the conditions of virus infec-
ion during natural transmission. Because the conditions
f infection in most in vitro neutralization assays provide
iruses with many growth advantages unlikely to exist in
ivo (4, 5, 8, 45), it is likely that these assays underesti-
ate the magnitude of the protective immune response
hat can be achieved in humans. Until experimental par-
digms that accurately duplicate the conditions of natu-
r
H
l
r
e
m
s
c
n
q
a
s
u
p
f
m
e
m
w
e
u
b
p
t
a
l
p
t
t
b
n
o
a
a
v
R
S
H
g
n
c
u
(
P
C
i
3
(
a
t
L
a
w
t
o
a
T
H
b
v
r
(
a
w
w
t
p
m
c
s
w
a
a
q
s
a
t
t
i
r
p
v
p
s
d
m
P
i
7RAPID COMMUNICATIONal infection can be established, the only way to establish
IV-1 vaccine efficacy is through human clinical trials.
Materials and Methods. Animals. Sixteen New Zea-
and white rabbits (2–3 months of age, 2.5–4.5 kg) were
andomly distributed into seven groups of two rabbits
ach. For each immunization, the rabbits were injected at
ultiple sites (intramuscular and subcutaneous) as de-
cribed previously (7). Antigens were emulsified in 50%
omplete Freund’s complete adjuvant for the first immu-
ization and incomplete Freund’s adjuvant for subse-
uent booster injections. The animals were immunized
nd bled at 14-day intervals. Serum was prepared by
tandard techniques and was stored frozen at 220°C
ntil needed.
Vaccine Antigens. Recombinant HIV-1 envelope glyco-
roteins (MN-rgp120 and A244-rgp120) were purified
rom transfected CHO cell lines by immunoaffinity chro-
atography as described previously (7, 23). Seven differ-
nt formulations of vaccine antigen were prepared by
ixing different amounts of MN-rgp120 with A244-rgp120
hile keeping the total amount of rgp120 contained in
ach injection constant at 300 mg/dose. The gp120s
sed in this study were at least 90% pure as determined
y sodium dodecyl sulfate–polyacrylamide gel electro-
horesis.
Analysis of Antisera. Sera were analyzed for the rela-
ive concentration of antibodies to each of the rgp120
ntigens (MN-rgp120 and A244-rgp120) by enzyme
inked immunoadsorbtion assay (ELISA) as described
reviously (34, 35).
Virus Culture and Neutralization Assays. Antisera were
ested for virus neutralization using methods similar to
hose described previously (43). Viruses were classified
y their suppliers as exhibiting syncytium-inducing or
on-syncytium-inducing phenotypes (21). The sensitivity
f viruses to inhibition by CD4-IgG was measured using
ssays similar to those described by Daar et al. (11; see
lso Ref. 2). The chemokine coreceptor used by each
irus was determined by assessing its sensitivity to
antes, indicating CCR5 receptor usage (10, 15), or to
DF, indicating CXCR4 receptor usage (12).
Virus neutralization assays using the MN strain of
IV-1 were carried out in PBMCs using a virus stock
rown in H9 cells as described previously (43). Virus
eutralization assays for all other viruses described were
arried out in PHA-activated PBMCs, from a single donor,
sing a method similar to that described by Wrin et al.
43). All virus stocks were prepared from cultures of
HA-activated PBMC cells, with the exception of the
M244 stock that was produced in PM-1 cells express-
ng the CXCR4 and CCR5 chemokine receptors (24). The
01660 (14), 302051 (CMV08) (44), and 302031 (CMV01)
44) strains of HIV-1 were obtained from the AIDS Re-
gent Program (National Institute of Allergy and Infec-ious Diseases). The BZ167 (GenBank Accession No.
22087), TH92009 (GenBank Accession No. U08830),
nd TH92014 (GenBank Accession No. U08801) viruses
ere obtained from the World Health Organization. Cul-
ures of CM 244 (GenBank Accession No. L03704) were
btained from F. McCutchan (Henry Jackson Foundation)
nd M. Norcross (U.S. Food and Drug Administration).
he JRcsf strain (GenBank Accession No. M38429) of
IV-1 (GenBank Accession No. M38429) was provided
y I. S. Y. Chen (University of California, Los Angeles). For
irus neutralization assays, quadruplicate aliquots of vi-
us were incubated with serial dilutions of test antiserum
37°C for 1 h) and PHA-activated PBMCs were then
dded (2.5 3 105 cells per 250 ml per well). The culture
as continued for 3 days, at which time the cells were
ashed to remove virus and antiserum. Cultures were
hen washed three times by centrifugation in microtiter
lates (300 g for 7 min) and resuspended in growth
edium containing interleukin 2. Extensive washing was
ritical in control experiments containing HIV-11 human
erum to ensure that antibody directed against HIV-1 p24
ould not interfere with the ultimate detection of the p24
ntigen. The washed cultures were incubated for an
dditional day. Accumulated p24 antigen was subse-
uently detected by enzyme-linked immunosorbent as-
ay (Coulter Corp., Hialeah, FL). Maximal p24 antigen
ccumulation was determined from cultures incubated in
he absence of antiserum (virus control), and test cul-
ures were subsequently diluted for analysis of neutral-
zation. Neutralization titers reported represent the recip-
ocal of antibody dilutions giving 50% inhibition of p24
roduction. In control experiments, baseline values for
irus replication were determined by measurement of
24 production in cultures without added antibody. All
era tested were prescreened for cell toxicity in a MTT
ye conversion assay. Control experiments involving im-
unoadsorbtion with Protein A–Sepharose (Pharmacia,
iscataway, NJ) were carried out to verify that neutraliz-
ng activity could be attributed to IgG.
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